University of Tasmania
Browse

Bertilimumab (Cambridge Antibody Technology Group)

journal contribution
posted on 2023-05-26, 10:28 authored by Ding, C, Li, J, Zhang, X
Cambridge Antibody Technology (CAT) is developing bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.

History

Publication title

Current Opinion in Investigational Drugs

Volume

5

Article number

11

Number

11

Pagination

1213-1219

ISSN

1472-4472

Publication status

  • Published

Repository Status

  • Restricted

Usage metrics

    University Of Tasmania

    Categories

    No categories selected

    Keywords

    No keyword provided

    Licence

    In Copyright

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC